close-icon

MHQ: Clinical IntelligencePowered by SurvivorNet

  • health-panel

    Health Panel

  • clinical-trial

    Clinical Trials

    ?
Prefer to talk instead of typing?
close-icon

Answers offered are informational and do not constitute medical advice. Learn more

close-icon
Health Profile

Enter health info to personalize results.

What is your gender?

What is your age?

close-icon
Clinical Trials

clinical-icon

filter

Clear List

Ask me anything about your health...

I’m listening

thinking

responding

close-icon close-icon
close-icon
close-icon
close-icon
left-icon Back to Results

Dr. Elizabeth Brem

location-icon

Orange, CA

LOCATION OF PRACTICE
Uci Health
MEDICAL Specialty:

Non-hodgkin Lymphoma



NPI Number
1578883781
ABOUT

Elizabeth Brem, MD is a hematologist-oncologist specializing in the treatment of lymphoma and other hematologic malignancies. Dr. Brem’s research focuses on on lymphoma and BCL-2 family proteins in the regulation of apoptosis, or normal cell death. Dr. Brem also serves as an assistant professor in the Division of Hematology/Oncology in the UC Irvine School of Medicine.

Dr. Brem received her medical degree from the University at Buffalo Jacobs School of Medicine and Biomedical Sciences.

Dr. Elizabeth Brem profile image

Published Articles

Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin Lymphoma.- 2026 Feb 2
Recurrent plasma cell myeloma with intracytoplasmic Auer rod-like inclusions after autologous hematopoietic stem cell transplantation.- 2025
Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis.- 2025 Aug
Lite-BEAM expands autologous stem cell transplantation access for older or unfit patients with lymphoma.- 2025 Dec
R-DA-EPOCH Versus DA-EPOCH-R: Impact of Chemoimmunotherapy Sequencing on Treatment Outcomes in Patients With Diffuse Large B-Cell Lymphoma.- 2025 Dec
A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy.- 2024 Dec
Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis.- 2025 Jun
Preclinical Experience Using 4D Intracardiac Echocardiography to Guide Cardiac Electrophysiology Procedures.- 2025 Feb
CNS prophylaxis is (mostly) futile in DLBCL.- 2024 Oct 1
Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd-Generation Bruton Tyrosine Kinase Inhibitor-Based Therapies.- 2024 Oct

Clinical Trials

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

Other Specialists treating Non-Hodgkin Lymphoma in Orange, CA

See All Doctors

Dr. Lauren Pinter-Brown

Specialty: Hematology, Oncology

My Resources
location-icon

UCI Health

My Resources

Dr. Edward Nelson

Specialty: Oncology

My Resources
location-icon

UCI Health

My Resources

Dr. Krushangi Patel

Specialty: Oncology

My Resources
location-icon

City of Hope

My Resources

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider